Magnesium chloride

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Magnesium chloride
Accession Number
DB09407
Type
Small Molecule
Groups
Approved
Description

Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water.

Structure
Thumb
Synonyms
  • Anhydrous magnesium chloride
  • Magnesium chloride anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Magnesium chloride hexahydrate02F3473H9O7791-18-6DHRRIBDTHFBPNG-UHFFFAOYSA-L
Magnesium chloride hydrateNot Available22756-14-5MJMDTFNVECGTEM-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
Chloride ionionicQ32ZN4869816887-00-6VEXZGXHMUGYJMC-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepasium Sup 100mgSuppositoryRectalLaboratoires Cortunon Inc.1980-12-311998-09-29Canada
ChloromagInjection, solution200 mg/1mLIntravenousMerit Pharmaceuticals2011-06-11Not applicableUs
Magnesium ChlorideInjection200 mg/1mLIntravenousMylan Teoranta2013-03-142015-01-15Us
Magnesium ChlorideInjection, solution200 mg/1mLIntravenousAmerican Therapeutic Medicines Inc.2009-05-012010-12-30Us
Magnesium ChlorideInjection200 mg/1mLIntravenousMylan Institutional LLC2013-03-14Not applicableUs
Magnesium ChlorideInjection, solution200 mg/1mLIntravenousAmerican Regent1990-09-302014-08-01Us
Magnesium ChlorideInjection, solution200 mg/1mLIntravenousClaris Lifesciences Limited2009-10-072010-11-04Us
Magnesium ChlorideInjection, solution200 mg/1mLIntravenousThe Torrance Company1990-09-032016-11-18Us
Magnesium-35 0.25 - 4.5Powder, for solutionHemodialysisAlthin Biopharm Inc.1988-12-311999-09-23Canada
Magnesium-35 0.5 - 4.5Powder, for solutionHemodialysisBaxter Laboratories1990-12-312002-08-01Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Formule 454LiquidOralLe Naturiste J.M.B. Inc.1980-12-312002-01-10Canada
Magnesium Chloride 606.5mgTabletOralBio Vita1987-12-312006-07-27Canada
Magnesium Liq 2.87mg/mlLiquidOralVitalab1990-12-312005-07-12Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2.5% Travasol Amino Acid Injection With Electrolytes In 10% DextroseMagnesium chloride (25.5 mg) + Arginine (290 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Alanine (520 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Valine (145 mg) + Methionine (100 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Tyrosine (10 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose ClinimixMagnesium chloride (25.5 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Alanine (520 mg) + L-Leucine hydrochloride (155 mg) + L-Lysine hydrochloride (145 mg) + Phenylalanine hydrochloride (155 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Valine (115 mg) + Methionine (145 mg) + Proline (105 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Tyrosine (10 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312015-08-05Canada
2.5%travasol Amino Acid InJ.W.eleC.W.25%dexMagnesium chloride (25.5 mg) + Arginine (290 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Alanine (520 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Valine (145 mg) + Methionine (100 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Tyrosine (10 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travas. Amino Acid InJ.W.elecw.25%dexMagnesium chloride (51 mg) + Arginine (316 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Alanine (570 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Threonine (115.5 mg) + L-Tryptophan (49.5 mg) + L-Valine (159.5 mg) + Methionine (110 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Tyrosine (11 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose QuickmixMagnesium chloride (51 mg) + Arginine (285 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Alanine (570 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Threonine (115 mg) + L-Tryptophan (49.5 mg) + L-Valine (126 mg) + Methionine (159 mg) + Proline (115 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Tyrosine (11 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-02-022007-08-02Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose QuickmixMagnesium chloride (51 mg) + Arginine (285 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (215.5 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Alanine (570 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Threonine (115 mg) + L-Tryptophan (49.5 mg) + L-Valine (126 mg) + Methionine (159 mg) + Proline (115 mg) + Sodium acetate (256 mg) + Sodium chloride (112 mg) + Tyrosine (11 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312007-08-02Canada
2.75%travasol Amino Acid InJ.W.eleC.W.5%dex.Magnesium chloride (51 mg) + Arginine (316 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Alanine (570 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Threonine (115.5 mg) + L-Tryptophan (49.5 mg) + L-Valine (159.5 mg) + Methionine (110 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215 mg) + Sodium chloride (112 mg) + Tyrosine (11 mg)LiquidIntravenousClintec Nutrition Company1996-12-311999-08-10Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 10% DextroseMagnesium chloride (51 mg) + Arginine (489 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Alanine (880 mg) + L-Leucine (310 mg) + L-Lysine hydrochloride (246.5 mg) + L-Phenylalanine (238 mg) + L-Threonine (178.5 mg) + L-Tryptophan (76.5 mg) + L-Valine (246.5 mg) + Methionine (170 mg) + Proline (289 mg) + Serine (212.5 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Tyrosine (17 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 20% DextroseMagnesium chloride (51 mg) + Arginine (489 mg) + Dextrose, unspecified form (20 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Alanine (880 mg) + L-Leucine (310 mg) + L-Lysine hydrochloride (246.5 mg) + L-Phenylalanine (238 mg) + L-Threonine (178.5 mg) + L-Tryptophan (76.5 mg) + L-Valine (246.5 mg) + Methionine (170 mg) + Proline (289 mg) + Serine (212.5 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Tyrosine (17 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312007-08-02Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose QuickmixMagnesium chloride (51 mg) + Arginine (440 mg) + Dextrose, unspecified form (20 g) + Dipotassium phosphate (261 mg) + Glycine (880 mg) + Histidine (186 mg) + Isoleucine (203 mg) + L-Alanine (880 mg) + L-Leucine hydrochloride (263 mg) + L-Lysine hydrochloride (246 mg) + Phenylalanine hydrochloride (263 mg) + L-Threonine (178 mg) + L-Tryptophan (76 mg) + L-Valine (195 mg) + Methionine (246 mg) + Proline (178 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Tyrosine (17 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ChloromagMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousMerit Pharmaceuticals2011-06-11Not applicableUs
ClinimixMagnesium chloride hexahydrate (1.02 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Alanine (17.60 g/2L) + L-Leucine (6.20 g/2L) + L-Lysine (4.93 g/2L) + L-Phenylalanine (4.76 g/2L) + L-Threonine (3.57 g/2L) + L-Tryptophan (1.53 g/2L) + L-Valine (4.93 g/2L) + Methionine (3.40 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Tyrosine (0.34 g/2L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
ClinimixMagnesium chloride hexahydrate (0.51 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Alanine (5.70 g/1L) + L-Leucine (2.01 g/1L) + L-Lysine (2.00 g/1L) + L-Phenylalanine (1.54 g/1L) + L-Threonine (1.16 g/1L) + L-Tryptophan (0.50 g/1L) + L-Valine (1.60 g/1L) + Methionine (1.10 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Tyrosine (0.11 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
ClinimixMagnesium chloride hexahydrate (0.51 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Alanine (5.70 g/1L) + L-Leucine (2.01 g/1L) + L-Lysine (2.00 g/1L) + L-Phenylalanine (1.54 g/1L) + L-Threonine (1.16 g/1L) + L-Tryptophan (0.50 g/1L) + L-Valine (1.60 g/1L) + Methionine (1.10 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Tyrosine (0.11 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
Cytosol Ophthalmics - Balanced Salt SolutionMagnesium chloride hexahydrate (30 mg/1mL) + Calcium chloride dihydrate (48 mg/1mL) + Potassium chloride (75 mg/1mL) + Sodium acetate trihydrate (3.90 mg/1mL) + Sodium chloride (6.40 mg/1mL) + Sodium citrate dihydrate (1.70 mg/1mL)SolutionIrrigationBiomet Biologics2010-01-012010-09-04Us
Dianeal for Peritoneal DialysisMagnesium chloride hexahydrate (0.051 g/1000mL) + Calcium chloride dihydrate (0.184 g/1000mL) + D-glucose (38.6 g/1000mL) + Sodium lactate (4.48 g/1000mL) + Sodium chloride (5.38 g/1000mL)Injection, solutionIntraperitonealBaxter Healthcare Corporation2014-10-27Not applicableUs
Dianeal for Peritoneal DialysisMagnesium chloride hexahydrate (0.051 g/1000mL) + Calcium chloride dihydrate (0.184 g/1000mL) + D-glucose (22.7 g/1000mL) + Sodium lactate (4.48 g/1000mL) + Sodium chloride (5.38 g/1000mL)Injection, solutionIntraperitonealBaxter Healthcare Corporation2014-10-27Not applicableUs
Dianeal for Peritoneal DialysisMagnesium chloride hexahydrate (0.051 g/1000mL) + Calcium chloride dihydrate (0.184 g/1000mL) + D-glucose (13.6 g/1000mL) + Sodium lactate (4.48 g/1000mL) + Sodium chloride (5.38 g/1000mL)Injection, solutionIntraperitonealBaxter Healthcare Corporation2014-10-27Not applicableUs
Hyperlyte CRMagnesium chloride hexahydrate (0.51 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Potassium acetate (1.96 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL) + Sodium chloride (1.17 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousAmerican Therapeutic Medicines Inc.2009-05-012010-12-30Us
Categories
UNII
59XN63C8VM
CAS number
7786-30-3
Weight
Average: 95.211
Monoisotopic: 93.922747312
Chemical Formula
Cl2Mg
InChI Key
TWRXJAOTZQYOKJ-UHFFFAOYSA-L
InChI
InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2
IUPAC Name
magnesium(2+) ion dichloride
SMILES
[Mg++].[Cl-].[Cl-]

Pharmacology

Indication

Magnesium chloride is used in several medical and topical (skin related) applications. Magnesium chloride usp, anhydrous uses as electrolyte replenisher, pharmaceutic necessity for hemodialysis and peritoneal dialysis fluids.

Associated Conditions
Associated Therapies
Pharmacodynamics

Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).

Mechanism of action

Mechanism of action of magnesium chloride studied in 10 adult volunteers. Results suggested magnesium ion in duodenum is relatively weak stimulus to pancreas and gall bladder. It is weak stimulant to cholecystokinin release and inhibits net jejunal water absorption. The oral administration of a single 800 mg dose of magnesium chloride in healthy volunteers resulted in a diminished rate of intraluminal lipid and protein digestion. The most pronounced effect of magnesium chloride, however, was a decreased gastric emptying rate of both test meals. After correction for gastric emptying, no differences were noted in intraluminal lipid or protein digestion. Therefore, the lower lipid levels noted after magnesium supplementation are unlikely to be the result of altered lipid assimilation. Magnesium chloride slows gastric emptying but does not influence lipid digestion.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Oral: Inversely proportional to amount ingested; 40% to 60% under controlled dietary conditions; 15% to 36% at higher doses

Volume of distribution

Bone (50% to 60%); extracellular fluid (1% to 2%)

Protein binding

30%, to albumin

Metabolism

Magnesium levels are efficiently regulated by the kidneys. Magnesium also undergoes efficient enterohepatic circulation

Route of elimination

Magnesium is excreted in urine. Unabsorbed magnesium is excreted in feces

Half life

Elimination half-life has been reported to be 27.7 hours following an overdose of 400 mEq magnesium in an adult.

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Toxicity

Mouse LD50 775mg/kg (intraperitoneal) Mouse LD50 : 7600mg/kg (oral) Rat LD 50 : 8100mg/kg (oral) Rat LD50 176mg/kg (intravenous) Severe toxicity occurs most often after intravenous infusions. It can also occur after chronic excessive oral doses, often in patients with renal insufficiency. Early manifestations are lethargy, hyporeflexia, followed by weakness, paralysis, hypotension, ECG changes (prolonged PR and QRS intervals), CNS depression, seizures, and respiratory depression. In overdose, magnesium impairs neuromuscular transmission, manifested as weakness and hyporeflexia.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1alpha-Hydroxyvitamin D5The serum concentration of Magnesium chloride can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2The serum concentration of Magnesium chloride can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
3-Aza-2,3-Dihydrogeranyl DiphosphateMagnesium chloride can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AbacavirAbacavir may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. DRUGS.COM [Link]
  3. Pubchem [Link]
  4. Toxnet [Link]
  5. ChemIDplus [Link]
External Links
KEGG Compound
C07755
PubChem Compound
5360315
PubChem Substance
347827844
ChemSpider
22987
ChEBI
6636
ChEMBL
CHEMBL2219642
Wikipedia
Magnesium_chloride
ATC Codes
A12CC01 — Magnesium chlorideB05XA11 — Magnesium chloride
AHFS Codes
  • 40:34.00* — Hemodialysis Solution
  • 88:29.00* — Minerals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHealthy Volunteers1
2CompletedPreventionAcute Kidney Injury (AKI)1
2CompletedTreatmentNeoplasms, Brain1
2CompletedTreatmentRespiratory Distress Syndrome, Adult1
2CompletedTreatmentΒ-Thalassemia Intermedia1
2Not Yet RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2RecruitingTreatmentAnterior Wall Myocardial Infarction1
2TerminatedTreatmentCongestive Heart Failure1
2, 3CompletedTreatmentStroke1
2, 3Not Yet RecruitingSupportive CareIschaemic Heart Diseases1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentCataracts2
3CompletedTreatmentContinuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / End Stage Renal Disease (ESRD)1
3CompletedTreatmentDiabetes Mellitus (DM) / ESRD1
3RecruitingTreatmentDelayed Graft Function / End Stage Kidney Disease / Kidney Transplant; Complications1
3TerminatedTreatmentCongestive Heart Failure1
4Active Not RecruitingTreatmentImpaired Renal Function1
4CompletedTreatmentAPD / Continuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / ESRD1
4CompletedTreatmentChronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
4RecruitingTreatmentHypovolaemia1
4TerminatedTreatmentHypertriglyceridemias / Peritoneal dialysis therapy1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntraocular
SolutionIntraocular
SolutionOphthalmic
Kit; solutionIntraocular
SolutionIntra-arterial
SuppositoryRectal
SolutionIrrigation
SolutionIntraperitoneal
Injection, solutionIntraperitoneal
LiquidHemodialysis
SolutionHemodialysis
SolutionIntrathecal
LiquidIntraperitoneal
SolutionHemodialysis; Intraperitoneal
LiquidIntraocular
SolutionIntravenous
InjectionIntravenous200 mg/1mL
Injection, solutionIntravenous200 mg/1mL
Tablet, coatedOral
TabletOral
Tablet, delayed releaseOral598 mg/1
LiquidOral
PowderHemodialysis
Powder, for solutionHemodialysis
TabletOral
LiquidBuccal
SprayBuccal
LiquidIntravenous
Kit; solutionIntraocular; Irrigation
Injection, solution, concentrateIntravenous
EmulsionIntravenous
IrrigantIrrigation
Injection, solutionIntravenous
Injection, solutionIntra-arterial
Solution
KitHemodialysis
SolutionHemodialysis; Intravenous
AerosolOral
InjectionIntravenous
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5945449No1999-08-312017-10-31Us
US7300674No2007-11-272023-03-04Us
US6077836No2000-06-202017-06-20Us
US6248726No2001-06-192018-06-19Us
US7084130No2006-08-012021-11-29Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.61ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity5.62 m3·mol-1ChemAxon
Polarizability2.39 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a lanthanide.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal salts
Sub Class
Alkaline earth metal chlorides
Direct Parent
Alkaline earth metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Alkaline earth metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
inorganic chloride, magnesium salt, magnesium halide (CHEBI:6636)

Drug created on November 30, 2015 12:10 / Updated on November 16, 2019 10:51